- NanoSyrinx has developed a novel drug delivery platform (a nanosyringe) that allows targeted delivery of biologics into diseased cells.
- The ability to specifically target a drug to diseased cells without affecting healthy ones is considered the Holy Grail for the treatment of complex diseases including cancer.
- Delivering functional biologics to the interiors of cells, via engineered protein ‘nanosyringes’, would open up an entirely new range of targets for drug development, that were previously inaccessible.
- The initial applications of this technology will be in the cell and gene therapy space (CGT), creating, for example, highly effective cancer treatments with significantly reduced side effects. Therefore, NanoSyrinx will likely face the strongest pull from the immuno-oncology and the CGT space – both multibillion-dollar markets.